***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 APRIL 2025**

Following is the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Ketoprofen | The sponsor requested the delisting of Orudis® SR 200 (Ketoprofen) from the Pharmaceutical Benefits Scheme (PBS).  The PBAC noted the moderate number of services in the last financial year and that there are alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need. |

Brendon Wheatley

Director (A/g), PBAC Governance

Office of Health Technology Assessment

Technology Assessment and Access Division

17 March 2025